Key Points

  • Daratumumab is well tolerated in patients with AL amyloidosis when used with appropriate preinfusion and postinfusion medications.

  • Daratumumab leads to rapid and deep hematologic responses in previously treated patients with AL amyloidosis.

Abstract

Daratumumab, a monoclonal CD38 antibody, is approved in the treatment of myeloma, but its efficacy and safety in light-chain (AL) amyloidosis has not been formally studied. This prospective phase 2 trial of daratumumab monotherapy for the treatment of AL amyloidosis was designed to determine the safety, tolerability, and hematologic and clinical response. Daratumumab 16 mg/kg was administered by IV infusion once weekly for weeks 1 to 8, every 2 weeks for weeks 9 to 24, and every 4 weeks thereafter until progression or unacceptable toxicity, for up to 24 months. Twenty-two patients with previously treated AL amyloidosis were enrolled. The majority of the patients had received high-dose melphalan and stem cell transplantation and/or treatment with a proteasome inhibitor. The median time between prior therapy and trial enrollment was 9 months (range, 1-180 months). No grade 3-4 infusion-related reactions occurred. The most common grade ≥3 adverse events included respiratory infections (n = 4; 18%) and atrial fibrillation (n = 4, 18%). Hematologic complete and very-good-partial response occurred in 86% of patients. The median time to first and best hematologic response was 4 weeks and 3 months, respectively. Renal response occurred in 10 of 15 patients (67%) with renal involvement and cardiac response occurred in 7 of 14 patients (50%) with cardiac involvement. In summary, daratumumab is well tolerated in patients with relapsed AL amyloidosis and leads to rapid and deep hematologic responses and organ responses. This trial was registered at www.clinicaltrials.gov as #NCT02841033.

REFERENCES

REFERENCES
1.
Merlini
G
,
Dispenzieri
A
,
Sanchorawala
V
, et al
.
Systemic immunoglobulin light chain amyloidosis
.
Nat Rev Dis Primers
.
2018
;
4
(
1
):
38
.
2.
Sanchorawala
V
,
Sun
F
,
Quillen
K
,
Sloan
JM
,
Berk
JL
,
Seldin
DC
.
Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience
.
Blood
.
2015
;
126
(
20
):
2345
-
2347
.
3.
Palladini
G
,
Milani
P
,
Foli
A
, et al
.
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach
.
Haematologica
.
2014
;
99
(
4
):
743
-
750
.
4.
Palladini
G
,
Sachchithanantham
S
,
Milani
P
, et al
.
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis
.
Blood
.
2015
;
126
(
5
):
612
-
615
.
5.
Sanchorawala
V
,
Shelton
AC
,
Lo
S
,
Varga
C
,
Sloan
JM
,
Seldin
DC
.
Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial
.
Blood
.
2016
;
128
(
8
):
1059
-
1062
.
6.
Sanchorawala
V
,
Palladini
G
,
Kukreti
V
, et al
.
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis
.
Blood
.
2017
;
130
(
5
):
597
-
605
.
7.
Reece
DE
,
Hegenbart
U
,
Sanchorawala
V
, et al
.
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis
.
Blood
.
2014
;
124
(
16
):
2498
-
2506
.
8.
Sanchorawala
V
,
Wright
DG
,
Rosenzweig
M
, et al
.
Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial
.
Blood
.
2007
;
109
(
2
):
492
-
496
.
9.
Nooka
AK
,
Kaufman
JL
,
Hofmeister
CC
, et al
.
Daratumumab in multiple myeloma
.
Cancer
.
2019
;
125
(
14
):
2364
-
2382
.
10.
Matsuda
M
,
Gono
T
,
Shimojima
Y
,
Hoshii
Y
,
Ikeda
S
.
Phenotypic analysis of plasma cells in bone marrow using flow cytometry in AL amyloidosis
.
Amyloid
.
2003
;
10
(
2
):
110
-
116
.
11.
Abeykoon
JP
,
Zanwar
S
,
Dispenzieri
A
, et al
.
Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis
.
Leukemia
.
2019
;
33
(
2
):
531
-
536
.
12.
Gran
C
,
Gahrton
G
,
Alici
E
,
Nahi
H
.
Case report: treatment of light-chain amyloidosis with daratumumab monotherapy in two patients
.
Eur J Haematol
.
2018
;
100
(
4
):
386
-
388
.
13.
Kaufman
GP
,
Schrier
SL
,
Lafayette
RA
,
Arai
S
,
Witteles
RM
,
Liedtke
M
.
Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis
.
Blood
.
2017
;
130
(
7
):
900
-
902
.
14.
Khouri
J
,
Kin
A
,
Thapa
B
, et al
.
Daratumumab proves safe and highly effective in AL amyloidosis
.
Br J Haematol
.
2019
;
185
(
2
):
342
-
344
.
15.
Kumar
S
,
Paiva
B
,
Anderson
KC
, et al
.
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
.
Lancet Oncol
.
2016
;
17
(
8
):
e328
-
e346
.
16.
Palladini
G
,
Dispenzieri
A
,
Gertz
MA
, et al
.
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes
.
J Clin Oncol
.
2012
;
30
(
36
):
4541
-
4549
.
17.
Palladini
G
,
Hegenbart
U
,
Milani
P
, et al
.
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis
.
Blood
.
2014
;
124
(
15
):
2325
-
2332
.
18.
Janssen Biotech, Inc
.
Dosing and administration for Darzalex (daratumumab)
. https://www.darzalexhcp.com/sites/www.darzalexhcp.com/files/darzalex_dosing_guide1.pdf?v=91.
Accessed 20 August 2019
.
19.
Joseph
NS
,
Kaufman
JL
.
Novel approaches for the management of AL amyloidosis
.
Curr Hematol Malig Rep
.
2018
;
13
(
3
):
212
-
219
.
20.
Palumbo
A
,
Chanan-Khan
A
,
Weisel
K
, et al;
CASTOR Investigators
.
Daratumumab, bortezomib, and dexamethasone for multiple myeloma
.
N Engl J Med
.
2016
;
375
(
8
):
754
-
766
.
21.
Usmani
SZ
,
Nahi
H
,
Mateos
M-V
, et al
.
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma
.
Blood
.
2019
;
134
(
8
):
668
-
677
.
22.
Janssen Biotech, Inc
.
Darzalex: redefining approaches in early-line multiple myeloma treatment
. https://www.darzalexhcp.com/.
Accessed 20 August 2019
.
23.
Johnsrud
AJ
,
Johnsrud
JJ
,
Susanibar
SA
, et al
.
Infectious and immunological sequelae of daratumumab in multiple myeloma
.
Br J Haematol
.
2019
;
185
(
1
):
187
-
189
.
24.
Kaufman
GP
,
Dispenzieri
A
,
Gertz
MA
, et al
.
Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis
.
Am J Hematol
.
2015
;
90
(
3
):
181
-
186
.
25.
Sanchorawala
V
.
Delay treatment of AL amyloidosis at relapse until symptomatic: devil is in the details
.
Blood Adv
.
2019
;
3
(
2
):
216
-
218
.
26.
Qualls
DA
,
Lewis
GD
,
Sanchorawala
V
,
Staron
A
.
Orthotopic heart transplant rejection in association with immunomodulatory therapy for AL amyloidosis: a case series and review of the literature
.
Am J Transplant
.
2019
;
19
(
11
):
3185
-
3190
.
You do not currently have access to this content.

Sign in via your Institution

Sign In